skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 350,652  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: subject: Middle Aged remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Material Type:
Article 		Add to My Research

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Annals of the rheumatic diseases, 2020-12, Vol.79 (12), p.1544-1549 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage? ;Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2020-218296 ;PMID: 32796045

Full text available

Citations Cited by
2
Listeria monocytogenes-associated respiratory infections: a study of 38 consecutive cases
Listeria monocytogenes-associated respiratory infections: a study of 38 consecutive cases
Material Type:
Article 		Add to My Research

Listeria monocytogenes-associated respiratory infections: a study of 38 consecutive cases

Clinical microbiology and infection, 2018-12, Vol.24 (12), p.1339.e1-1339.e5 [Peer Reviewed Journal]

Attribution - NonCommercial ;ISSN: 1198-743X ;EISSN: 1469-0691 ;DOI: 10.1016/j.cmi.2018.03.003 ;PMID: 29549058

Digital Resources/Online E-Resources

Citations Cited by
3
Pine bark (Pinus spp.) extract for treating chronic disorders
Pine bark (Pinus spp.) extract for treating chronic disorders
Material Type:
Article 		Add to My Research

Pine bark (Pinus spp.) extract for treating chronic disorders

Cochrane database of systematic reviews, 2020-09, Vol.2020 (9), p.CD008294 [Peer Reviewed Journal]

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD008294.pub5 ;PMID: 32990945

Full text available

Citations Cited by
4
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
Material Type:
Article 		Add to My Research

COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series

Clinical rheumatology, 2020-11, Vol.39 (11), p.3195-3204 [Peer Reviewed Journal]

The Author(s) 2020 ;The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0770-3198 ;EISSN: 1434-9949 ;DOI: 10.1007/s10067-020-05334-7 ;PMID: 32852623

Full text available

Citations Cited by
5
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
Material Type:
Article 		Add to My Research

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

British journal of cancer, 2020-12, Vol.123 (12), p.1730-1736 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-020-01077-z ;PMID: 32989226

Full text available

Citations Cited by
6
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Material Type:
Article 		Add to My Research

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Annals of oncology, 2015-08, Vol.26 (8), p.1766-1771 [Peer Reviewed Journal]

2015 European Society for Medical Oncology ;The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdv237 ;PMID: 26105599

Full text available

Citations Cited by
7
Trial of Pimavanserin in Dementia-Related Psychosis
Trial of Pimavanserin in Dementia-Related Psychosis
Material Type:
Article 		Add to My Research

Trial of Pimavanserin in Dementia-Related Psychosis

The New England journal of medicine, 2021-07, Vol.385 (4), p.309-319 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;Copyright ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034634 ;PMID: 34289275

Full text available

Citations Cited by
8
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Material Type:
Article 		Add to My Research

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

The lancet oncology, 2016-07, Vol.17 (7), p.976-983 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 01, 2016 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(16)30053-5 ;PMID: 27267608 ;CODEN: LANCAO

Full text available

Citations Cited by
9
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Material Type:
Article 		Add to My Research

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2017-06, Vol.35 (18), p.2028-2036 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2016.70.1508 ;PMID: 28463630

Full text available

Citations Cited by
10
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Material Type:
Article 		Add to My Research

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Annals of oncology, 2018-10, Vol.29 (10), p.2052-2060 [Peer Reviewed Journal]

2018 THE AUTHORS ;The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 2018 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy264 ;PMID: 30052729

Full text available

Citations Cited by
11
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Material Type:
Article 		Add to My Research

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19

Antimicrobial agents and chemotherapy, 2020-08, Vol.64 (9) [Peer Reviewed Journal]

Copyright © 2020 American Society for Microbiology. ;Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/AAC.01061-20 ;PMID: 32661006

Full text available

Citations Cited by
12
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
Material Type:
Article 		Add to My Research

Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Annals of the Rheumatic Diseases, 2020-11, Vol.79 (11), p.1393-1399 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.bmj.com/company/legal-information ;This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage? ;Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2020-217984 ;PMID: 32769150

Digital Resources/Online E-Resources

Citations Cited by
13
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Material Type:
Article 		Add to My Research

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3167-3175 [Peer Reviewed Journal]

2015 INIST-CNRS ;2010 by American Society of Clinical Oncology 2010 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2009.26.7609 ;PMID: 20516446

Full text available

Citations Cited by
14
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Material Type:
Article 		Add to My Research

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)

British journal of cancer, 2017-06, Vol.117 (1), p.33-40 [Peer Reviewed Journal]

Copyright Nature Publishing Group Jun 27, 2017 ;Copyright © 2017 Cancer Research UK 2017 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2017.145 ;PMID: 28588322

Full text available

Citations Cited by
15
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Material Type:
Article 		Add to My Research

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

The New England journal of medicine, 2017-01, Vol.376 (1), p.32-40 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1611688 ;PMID: 27959717

Full text available

Citations Cited by
16
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
Material Type:
Article 		Add to My Research

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.712-719 [Peer Reviewed Journal]

Copyright Elsevier Limited Mar 1, 2005 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2004.10.068 ;PMID: 15734615

Full text available

Citations Cited by
17
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Material Type:
Article 		Add to My Research

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2103425 ;PMID: 34818478

Full text available

Citations Cited by
18
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Material Type:
Article 		Add to My Research

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Annals of the rheumatic diseases, 2020-07, Vol.79 (7), p.859-866 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage? ;Distributed under a Creative Commons Attribution 4.0 International License ;Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2020-217871 ;PMID: 32471903

Full text available

Citations Cited by
19
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Material Type:
Article 		Add to My Research

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2654-2663 [Peer Reviewed Journal]

2015 INIST-CNRS ;2012 by American Society of Clinical Oncology 2012 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.39.8545 ;PMID: 22711857

Full text available

Citations Cited by
20
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Material Type:
Article 		Add to My Research

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

The lancet oncology, 2016, Vol.17 (1), p.78-89 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 1, 2016 ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(15)00366-6 ;PMID: 26590673

Full text available

Citations Cited by

Results 1 - 20 of 350,652  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (327,743)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1974  (7,320)
  2. 1974 To 1985  (23,672)
  3. 1986 To 1997  (47,382)
  4. 1998 To 2010  (120,426)
  5. After 2010  (152,036)
  6. More options open sub menu

Subject 

  1. Humans  (350,634)
  2. Science & Technology  (298,255)
  3. Female  (294,271)
  4. Life Sciences & Biomedicine  (290,763)
  5. Male  (287,633)
  6. Adult  (220,691)
  7. Aged  (201,593)
  8. Biological And Medical Sciences  (109,379)
  9. Medical Sciences  (108,381)
  10. Treatment Outcome  (88,565)
  11. Aged, 80 And Over  (59,495)
  12. Adolescent  (58,824)
  13. Oncology  (53,877)
  14. Pharmacology. Drug Treatments  (53,084)
  15. Retrospective Studies  (44,967)
  16. Young Adult  (40,145)
  17. General & Internal Medicine  (38,796)
  18. Medicine, General & Internal  (35,472)
  19. Prospective Studies  (34,831)
  20. More options open sub menu

Language 

  1. English  (340,091)
  2. Japanese  (39,688)
  3. Spanish  (3,346)
  4. Portuguese  (3,092)
  5. French  (2,225)
  6. German  (2,123)
  7. Russian  (736)
  8. Chinese  (590)
  9. Italian  (531)
  10. Polish  (417)
  11. Norwegian  (355)
  12. Swedish  (226)
  13. Korean  (203)
  14. Turkish  (174)
  15. Serbian  (97)
  16. Ukrainian  (68)
  17. Czech  (59)
  18. Croatian  (45)
  19. Hungarian  (36)
  20. Dutch  (31)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait